Previous Article | Next Article ![]()
Journal of Clinical Microbiology, March 1999, p. 518-523, Vol. 37, No. 3
Departments of
Pathology,1
Microbiology/Immunology,4 and
Anatomy,3 University of Arkansas for
Medical Sciences, Little Rock, Arkansas, and
Duke University
Medical Center/Universidade Federal do Espirito Santo,
Vitória, Brazil2
Received 27 August 1998/Returned for modification 22 November
1998/Accepted 7 December 1998
Numerous assays have been described for the detection of DNA and
rRNA sequences that are specific for the Mycobacterium
tuberculosis complex. Although beneficial to initial diagnosis,
such assays have proven unsuitable for monitoring therapeutic efficacy
owing to the persistence of these nucleic acid targets long after
conversion of smears and cultures to negative. However, prokaryotic
mRNA has a typical half-life of only a few minutes and we have
previously shown that the presence of mRNA is a good indicator of
bacterial viability. The purpose of the present study was to develop a
novel reverse transcriptase-strand displacement amplification system for the detection of M. tuberculosis
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Detection of Viable Mycobacterium
tuberculosis by Reverse Transcriptase-Strand
Displacement Amplification of mRNA


-antigen (85B
protein) mRNA and to demonstrate the use of this assay in assessing
chemotherapeutic efficacy in patients with pulmonary tuberculosis. The
assay was applied to sequential, noninduced sputum specimens collected
from four patients: 10 of 11 samples (91%) collected prior to the
start of therapy were positive for alpha-antigen mRNA, compared with 1 of 8 (13%), 2 of 8 (25%), 2 of 8 (25%), and 0 of 8 collected on days
2, 4, 7, and 14 of treatment, respectively. In contrast, 39 of 44 samples (89%) collected on or before day 14 were positive for
-antigen DNA. The loss of detectable mRNA corresponded to a rapid
drop over the first 4 days of treatment in the number of viable
organisms present in each sputum sample, equivalent to a mean fall of
0.43 log10 CFU/ml/day. Analysis of mRNA is a potentially
useful method for monitoring therapeutic efficacy and for rapid in
vitro determination of drug susceptibility.
*
Corresponding author. Mailing address: John L. McClellan Memorial Veterans' Hospital, Slot-151, 4300 West 7th St.,
Little Rock, AR 72205. Phone: (501) 257-4827. Fax: (501)
664-6748. E-mail: eisenachkathleend{at}exchange.uams.edu.
Present address: Becton Dickinson Microbiology Systems, Sparks, Md.
Present address: University of Iowa, Iowa City, Iowa.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»